Hedge Fund - Broadfin Capital

Kevin Kotler’s Broadfin Capital LLC, one of the leading healthcare-focused hedge funds, disclosed its ownership of nearly 1.48 million shares in Medgenics Inc.

Kevin Kotler’s Broadfin Capital has filed a 13D with the Securities and Exchange Commission regarding its stake in Recro Pharma Inc. (NASDAQ:REPH).

Broadfin Capital, led by Kevin Kotler, has initiated a new position in QLT Inc. (USA) (NASDAQ:QLTI). In a new filing with the U.S.

According to a recent 13G form filed with the Securities and Exchange Commission, Kevin Kotler's Broadfin Capital has initiated a stake in ContraFect Corp (NASDAQ:CFRX) to the tune of 1.42 million shares...

Broadfin Capital, LLC is a New York-based hedge fund, whose $1.28-billion equity portfolio is invested in healthcare companies.

To say Kevin Kotler’s Broadfin Capital had exceptional Q1 returns from its 11 long positions in companies valued at $1 billion or more would be a gross understatement.

Kevin Kotler's Broadfin Capital has disclosed raising its passive stake in the micro-cap oncology biotechnology company Ignyta Inc (NASDAQ:RXDX).

In two separate filings today Kevin Kotler's Broadfin Capital has revealed increasing its passive stake in Zogenix, Inc.

The days of having no fund activity in Epirus Biopharmaceuticals Inc (NASDAQ:EPRS) are over.